Mohammed Jamal

For the first time, allocators can instantly evaluate the authenticity of track records and the likelihood of future outperformance – addressing a multi-billion-dollar problem of misallocated capital each year.

OTS Capital is a quantitative hedge fund that provides a unique and ultra-diversified portfolio for family offices, sovereign wealth funds, HNW, UHNW, and institutional investors. Our Quantitative Hedge Fund is based in Luxembourg. We are part of a group of financial service companies that is able to leverage significantly off the group’s infrastructure, data & resources.

NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues. No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgos short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.

At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info.

BoltOS is a system upgrade for creators. Founded in 2017, BoltOS is a technology company that combines immersive streaming with accessible blockchain technology to create a unique ecosystem for creators, viewers, and advertisers. The heart of our ecosystem is the Bolt+ live streaming platform (boltplus.tv), which offers free, advertising-supported streaming from individual creators, some of the biggest media companies in the world, and everyone in between. At Bolt+, our unique immersive streaming technology empowers viewers to interact with content through features like Chat, Shop, Rewards, and AI. Bolt+ also hosts live events and subscription-only content, offering monetisation opportunities for creators. Weve also enabled programmatic advertising, enabling blue-chip advertisers to reach audiences on Bolt+. AI and ML implementations is enabled by our integration of 6 foundational models (including Claude and Llama3) across Bolt+. BoltChain, an Ethereum-compatible Blockchain with smart contract support, and BoltX, our digital asset wallet, come together with Bolt+ to supercharge the BoltOS offering. BoltOS has forged strategic relationships with over 180 TV brands, streaming partnerships with 50 media giants, and 30 technology partners. Some of our strategic partners include Bloomberg, Hisense Group, and One Football. At the heart of BoltOS is a diverse team that originates from 15 different countries, including alumni from Tencent, Twitter, and Goldman Sachs. BoltOS is headquartered in London, United Kingdom, and backed by Trovio Group , MBK Holdings (Qatar Royal Family), Primal Capital, and Plutus Investment Group. We have a diverse and inclusive team, where 40% of our executive leadership team are women. Links: boltos.ai, boltplus.tv, boltchain.com

The largest moving media network in the UK ready to make every mile count for our drivers and advertisers. For our brands we’re here to provide fast, effective out-of-home advertising. We supercharge campaign return on investment with our media assets providing advertisers access to the UK’s largest street-level audience. All our campaigns provide you real-time tracking. For our drivers we’re here to help you get more for the hours you spend on the road. Drovo drivers can increase their monthly income and offset their vehicle’s CO2 emissions at zero cost. All achieved through our mobile app. From a global perspective we’re the UK’s first carbon-neutral transit media provider. We offset every single campaign mile’s CO2 emissions, encourage electric vehicle adoption and support greener road initiatives. Ready to sustainably advertise with us?

BayBridgeDigital is a game changing new company that drives digital transformation to create new growth and business value faster. BayBridgeDigital connects organizations, brands, technology and people through design-driven transformation, creating amazing customer experiences and building digital products. We are specialized in Digital transformation leveraging Salesforce. BayBridgeDigital operates in America, Europe and Middle East.

For the first time, allocators can instantly evaluate the authenticity of track records and the likelihood of future outperformance – addressing a multi-billion-dollar problem of misallocated capital each year.

OTS Capital is a quantitative hedge fund that provides a unique and ultra-diversified portfolio for family offices, sovereign wealth funds, HNW, UHNW, and institutional investors. Our Quantitative Hedge Fund is based in Luxembourg. We are part of a group of financial service companies that is able to leverage significantly off the group’s infrastructure, data & resources.

NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues. No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgos short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford. Oxford Cancer Biomarkers range of predictive biomarkers will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 20 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. OncoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer.

At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info.